Alexandra J Stewart, Ciarna Brooker, Gemma Vose, Katie Redmond, Amy Williams, Nikesh Pankhania, Hayley Dommett, Justin Kirk-Bayley, Adrian P Franklin, Ben Morrison
Purpose: Intra-cavitary brachytherapy forms an essential part of the curative treatment of cervical and vaginal cancer, and can be used for cure or palliation in endometrial and vulval cancers. Removal of brachytherapy applicators is often performed after anaesthesia has worn off and can be an uncomfortable and anxiety-provoking procedure. In this paper, we present our experience in a series of patients before and after the introduction of inhaled methoxyflurane (IMF, Penthrox™).
Material and methods: Questionnaires were sent to patients prior to the introduction of IMF to retrospectively score pain and anxiety during the brachytherapy procedure. Following successful review by the local drugs and therapeutic committee as well as staff training, IMF was introduced and offered to patients during applicator removal. Prospective pain scores and retrospective questionnaires were collected. Pain was rated on a scale of 0 to 10, with zero being no pain and 10 being extreme pain.
Results: Thirteen patients returned retrospective questionnaires prior to IMF introduction and seven patients following IMF introduction. After the first brachytherapy insertion, the mean recollected pain score during applicator removal decreased from 6/10 to 1/10 (p = 0.002). The mean recollected pain score one hour after applicator removal reduced from 3/10 to 0 (p = 0.04). Prospective measurements for 77 insertions in 44 patients receiving IMF reported a median pain score of 1/10 immediately before applicator removal (range, 0-10), and 0/10 immediately after applicator removal (range, 0-5).
Conclusions: Inhaled methoxyflurane is easily administered and effective method of decreasing pain during applicator removal following gynecologic brachytherapy.
{"title":"Pain and symptom relief using inhaled methoxyflurane for gynecologic brachytherapy applicator removal.","authors":"Alexandra J Stewart, Ciarna Brooker, Gemma Vose, Katie Redmond, Amy Williams, Nikesh Pankhania, Hayley Dommett, Justin Kirk-Bayley, Adrian P Franklin, Ben Morrison","doi":"10.5114/jcb.2023.125581","DOIUrl":"https://doi.org/10.5114/jcb.2023.125581","url":null,"abstract":"<p><strong>Purpose: </strong>Intra-cavitary brachytherapy forms an essential part of the curative treatment of cervical and vaginal cancer, and can be used for cure or palliation in endometrial and vulval cancers. Removal of brachytherapy applicators is often performed after anaesthesia has worn off and can be an uncomfortable and anxiety-provoking procedure. In this paper, we present our experience in a series of patients before and after the introduction of inhaled methoxyflurane (IMF, Penthrox™).</p><p><strong>Material and methods: </strong>Questionnaires were sent to patients prior to the introduction of IMF to retrospectively score pain and anxiety during the brachytherapy procedure. Following successful review by the local drugs and therapeutic committee as well as staff training, IMF was introduced and offered to patients during applicator removal. Prospective pain scores and retrospective questionnaires were collected. Pain was rated on a scale of 0 to 10, with zero being no pain and 10 being extreme pain.</p><p><strong>Results: </strong>Thirteen patients returned retrospective questionnaires prior to IMF introduction and seven patients following IMF introduction. After the first brachytherapy insertion, the mean recollected pain score during applicator removal decreased from 6/10 to 1/10 (<i>p</i> = 0.002). The mean recollected pain score one hour after applicator removal reduced from 3/10 to 0 (<i>p</i> = 0.04). Prospective measurements for 77 insertions in 44 patients receiving IMF reported a median pain score of 1/10 immediately before applicator removal (range, 0-10), and 0/10 immediately after applicator removal (range, 0-5).</p><p><strong>Conclusions: </strong>Inhaled methoxyflurane is easily administered and effective method of decreasing pain during applicator removal following gynecologic brachytherapy.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/1e/JCB-15-50248.PMC10034726.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9198900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mark P Dumago, Kelvin Ken L Yu, Luisa E Jacomina, Eugene T Yap, Carl Jay E Jainar, Maureen R Bojador, Adrian F Fernando, Warren R Bacorro, Michael A Mejia
Purpose: To report technical details and 15-month outcomes of a patient with node-positive external auditory canal (EAC) squamous cell carcinoma (SCC) treated with definitive intracavitary high-dose-rate (HDR) brachytherapy to primary tumor, and external beam radiotherapy (EBRT) to draining lymphatics.
Material and methods: A 21-year-old male was diagnosed with SCC of the right EAC. The patient underwent definitive HDR intracavitary brachytherapy, 340 cGy/fraction for 14 twice-daily fractions, followed by EBRT using intensity-modulated radiation therapy (IMRT) to cover the grossly enlarged pre-auricular node, ipsilateral intra-parotid, and cervical lymph node levels II and III.
Results: The approved brachytherapy plan had an average high-risk clinical tumor volume (CTV-HR) D90 of 341 cGy with a total dose of 47.7 Gy (BED, 80.3 Gy, EQD2, 66.6 Gy). For the approved IMRT plan, the prescription to the involved right pre-auricular node was 66 Gy in 33 fractions, and more than 95% of the target received at least 62.7 Gy. High-risk nodal regions were simultaneously prescribed: 59.4 Gy in 1.8 Gy fractions, and more than 95% received at least 56.4 Gy. Organs at risk (OARs) were kept below their dose constraints.The patient tolerated both the procedures with no grade ≥ 2 treatment-related adverse events. Grade 1 dermatitis in the right pre-auricular and cervical areas during the course of EBRT was experienced. Fifteen months post-RT, the patient has no evidence of disease, and was noted to have EAC stenosis, which translated to moderate conductive hearing loss of the right ear. Thyroid function was normal at 15 months after EBRT.
Conclusions: This case report illustrates that the delivered definitive radiotherapy is technically feasible, effective, and well-tolerated in patients with SCC of EAC.
{"title":"Technical details and clinical outcomes after high-dose-rate intracavitary brachytherapy for squamous cell carcinoma of external auditory canal and external beam radiotherapy for nodal coverage: A case report.","authors":"Mark P Dumago, Kelvin Ken L Yu, Luisa E Jacomina, Eugene T Yap, Carl Jay E Jainar, Maureen R Bojador, Adrian F Fernando, Warren R Bacorro, Michael A Mejia","doi":"10.5114/jcb.2023.125481","DOIUrl":"https://doi.org/10.5114/jcb.2023.125481","url":null,"abstract":"<p><strong>Purpose: </strong>To report technical details and 15-month outcomes of a patient with node-positive external auditory canal (EAC) squamous cell carcinoma (SCC) treated with definitive intracavitary high-dose-rate (HDR) brachytherapy to primary tumor, and external beam radiotherapy (EBRT) to draining lymphatics.</p><p><strong>Material and methods: </strong>A 21-year-old male was diagnosed with SCC of the right EAC. The patient underwent definitive HDR intracavitary brachytherapy, 340 cGy/fraction for 14 twice-daily fractions, followed by EBRT using intensity-modulated radiation therapy (IMRT) to cover the grossly enlarged pre-auricular node, ipsilateral intra-parotid, and cervical lymph node levels II and III.</p><p><strong>Results: </strong>The approved brachytherapy plan had an average high-risk clinical tumor volume (CTV-HR) D<sub>90</sub> of 341 cGy with a total dose of 47.7 Gy (BED, 80.3 Gy, EQD<sub>2</sub>, 66.6 Gy). For the approved IMRT plan, the prescription to the involved right pre-auricular node was 66 Gy in 33 fractions, and more than 95% of the target received at least 62.7 Gy. High-risk nodal regions were simultaneously prescribed: 59.4 Gy in 1.8 Gy fractions, and more than 95% received at least 56.4 Gy. Organs at risk (OARs) were kept below their dose constraints.The patient tolerated both the procedures with no grade ≥ 2 treatment-related adverse events. Grade 1 dermatitis in the right pre-auricular and cervical areas during the course of EBRT was experienced. Fifteen months post-RT, the patient has no evidence of disease, and was noted to have EAC stenosis, which translated to moderate conductive hearing loss of the right ear. Thyroid function was normal at 15 months after EBRT.</p><p><strong>Conclusions: </strong>This case report illustrates that the delivered definitive radiotherapy is technically feasible, effective, and well-tolerated in patients with SCC of EAC.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/ec/JCB-15-50207.PMC10034724.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9198898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-01Epub Date: 2023-02-28DOI: 10.5114/jcb.2023.125582
Mingli Yuan, Liangchao Wang, Yang Xiao, Xiaoqun Guo, Yi Hu
Although immunotherapy regimens for advanced non-small-cell lung cancer (NSCLC) improve survival in selected sub-populations, their efficacy remains far from ideal due to underlying resistance; therefore, multimodal combination strategies are needed to optimize their efficacy. In our report, two patients with advanced NSCLC with negative targetable mutations, who had failed first-line chemotherapy were treated with combined therapy of computed tomography (CT)-guided percutaneous iodine-125 seed implantation and pembrolizumab. After combination treatment, both patients achieved partial response (PR), and sustained a long progression-free survival (PFS) without obvious therapy-related adverse reactions. Iodine-125 seeds bring no long-term adverse events and effectively amplify anti-tumor immune response induced by immunotherapy; thus, this combined therapy might be a promising alternative for NSCLC.
{"title":"Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy: A report of two cases and literature review.","authors":"Mingli Yuan, Liangchao Wang, Yang Xiao, Xiaoqun Guo, Yi Hu","doi":"10.5114/jcb.2023.125582","DOIUrl":"10.5114/jcb.2023.125582","url":null,"abstract":"<p><p>Although immunotherapy regimens for advanced non-small-cell lung cancer (NSCLC) improve survival in selected sub-populations, their efficacy remains far from ideal due to underlying resistance; therefore, multimodal combination strategies are needed to optimize their efficacy. In our report, two patients with advanced NSCLC with negative targetable mutations, who had failed first-line chemotherapy were treated with combined therapy of computed tomography (CT)-guided percutaneous iodine-125 seed implantation and pembrolizumab. After combination treatment, both patients achieved partial response (PR), and sustained a long progression-free survival (PFS) without obvious therapy-related adverse reactions. Iodine-125 seeds bring no long-term adverse events and effectively amplify anti-tumor immune response induced by immunotherapy; thus, this combined therapy might be a promising alternative for NSCLC.</p>","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8c/78/JCB-15-50249.PMC10034723.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9198903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Devin Van Elburg, Tyler Meyer, Kevin Martell, Sarah Quirk, Michael Roumeliotis
AMA Van Elburg D, Meyer T, Martell K, Quirk S, Roumeliotis M. Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.131781. APA Van Elburg, D., Meyer, T., Martell, K., Quirk, S., & Roumeliotis, M. (2023). Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.131781 Chicago Van Elburg, Devin, Tyler Meyer, Kevin Martell, Sarah Quirk, and Michael Roumeliotis. 2023. "Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.131781. Harvard Van Elburg, D., Meyer, T., Martell, K., Quirk, S., and Roumeliotis, M. (2023). Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.131781 MLA Van Elburg, Devin et al. "Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation." Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.131781. Vancouver Van Elburg D, Meyer T, Martell K, Quirk S, Roumeliotis M. Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.131781.
张建军,张建军,张建军,等。基于蒙特卡罗模拟的妇科模板间质高剂量近距离放疗对阴道黏膜的影响。当代近距离放射治疗杂志。2023。doi: 10.5114 / jcb.2023.131781。APA Van Elburg, D, Meyer, T, Martell, K, Quirk, S, and Roumeliotis, M.(2023)。应用蒙特卡罗模拟评估妇科模板间质高剂量率近距离放疗对阴道黏膜的剂量。当代近距离放射治疗杂志。https://doi.org/10.5114/jcb.2023.131781 Chicago Van Elburg, Devin, Tyler Meyer, Kevin Martell, Sarah Quirk和Michael Roumeliotis. 2023。应用蒙特卡罗模拟评估妇科模板间质高剂量率近距离放疗对阴道黏膜的剂量。当代近距离放射治疗杂志。doi: 10.5114 / jcb.2023.131781。哈佛范埃尔伯格博士,迈耶,T.,马泰尔,K.,夸克,S.,和Roumeliotis, M.(2023)。应用蒙特卡罗模拟评估妇科模板间质高剂量率近距离放疗对阴道黏膜的剂量。当代近距离放射治疗杂志。https://doi.org/10.5114/jcb.2023.131781 MLA Van Elburg, Devin等。使用蒙特卡罗模拟评估妇科模板间质高剂量率近距离放疗对阴道粘膜的剂量当代近距离放射治疗杂志,2023。doi: 10.5114 / jcb.2023.131781。vanvanelburg D, Meyer T, Martell K, Quirk S, Roumeliotis M.基于蒙特卡罗模拟的妇科模板间质高剂量近距离放疗阴道黏膜剂量评估。当代近距离放射治疗杂志。2023。doi: 10.5114 / jcb.2023.131781。
{"title":"Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation","authors":"Devin Van Elburg, Tyler Meyer, Kevin Martell, Sarah Quirk, Michael Roumeliotis","doi":"10.5114/jcb.2023.131781","DOIUrl":"https://doi.org/10.5114/jcb.2023.131781","url":null,"abstract":"AMA Van Elburg D, Meyer T, Martell K, Quirk S, Roumeliotis M. Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.131781. APA Van Elburg, D., Meyer, T., Martell, K., Quirk, S., & Roumeliotis, M. (2023). Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.131781 Chicago Van Elburg, Devin, Tyler Meyer, Kevin Martell, Sarah Quirk, and Michael Roumeliotis. 2023. \"Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation\". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.131781. Harvard Van Elburg, D., Meyer, T., Martell, K., Quirk, S., and Roumeliotis, M. (2023). Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.131781 MLA Van Elburg, Devin et al. \"Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation.\" Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.131781. Vancouver Van Elburg D, Meyer T, Martell K, Quirk S, Roumeliotis M. Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachytherapy using Monte Carlo simulation. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.131781.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136007884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David Miguel, Jesús María de Frutos, Pilar Alonso, Ciro García-Álvarez, María Antonia Saornil, Patricia Diezhandino, Maria Isabel Garavis, Patricia Valencia
Purpose The aim of this study was to analyze the course of visual acuity (VA) in visual outcomes of patients treated with iodine-125 (125I) brachytherapy in our center, based on original VA before treatment. Material and methods Visual acuity was prospectively assessed using a case series of 305 patients treated with 125I between 1996 and 2022. To examine how VA behaves over time, we divided patient sample into 4 groups: (1) Patients with visual acuity of less than V ≤ 0.1 at baseline; (2) Patients with low to moderate VA, ranging 0.1 < V < 0.4; (3) Patients with moderate-high VA, ranging 0.4 < V < 0.8; (4) Patients with very high VA of V > 0.8. Each of the four groups was studied separately over a 60-month period to determine the percentage of patients with VA improvement, worsening, or with the same VA status. Finally, visual outcomes over time were estimated with 95% confidence interval (CI) using Kaplan-Meier analysis, and VA maintenance rates were reported at 1, 3, 5, 10, 15, and 20 years of follow-up. Results The median follow-up time was 78.2 months (range, 6-254 months). The cumulative probabilities of survival analysis at 1, 3, 5, and 10 years were 16%, 3%, 2%, and none for the first sub-group; 46%, 20%, 17%, and 14% for the second; 65%, 53%, 29%, and 15% for the third; and 86%, 56%, 48%, and 41% for the fourth sub-group. The median survival in years was 0.30, 0.80, 3.10, and 4.40 for each sub-cohort, respectively. Conclusions The decrease and maintenance of VA depends on the initial VA of patients. Most patients experience a marked worsening of their VA, regardless of their VA status before treatment with episcleral brachytherapy. Patients with a higher baseline VA retain VA best over time.
{"title":"A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma","authors":"David Miguel, Jesús María de Frutos, Pilar Alonso, Ciro García-Álvarez, María Antonia Saornil, Patricia Diezhandino, Maria Isabel Garavis, Patricia Valencia","doi":"10.5114/jcb.2023.132658","DOIUrl":"https://doi.org/10.5114/jcb.2023.132658","url":null,"abstract":"Purpose The aim of this study was to analyze the course of visual acuity (VA) in visual outcomes of patients treated with iodine-125 (125I) brachytherapy in our center, based on original VA before treatment. Material and methods Visual acuity was prospectively assessed using a case series of 305 patients treated with 125I between 1996 and 2022. To examine how VA behaves over time, we divided patient sample into 4 groups: (1) Patients with visual acuity of less than V ≤ 0.1 at baseline; (2) Patients with low to moderate VA, ranging 0.1 < V < 0.4; (3) Patients with moderate-high VA, ranging 0.4 < V < 0.8; (4) Patients with very high VA of V > 0.8. Each of the four groups was studied separately over a 60-month period to determine the percentage of patients with VA improvement, worsening, or with the same VA status. Finally, visual outcomes over time were estimated with 95% confidence interval (CI) using Kaplan-Meier analysis, and VA maintenance rates were reported at 1, 3, 5, 10, 15, and 20 years of follow-up. Results The median follow-up time was 78.2 months (range, 6-254 months). The cumulative probabilities of survival analysis at 1, 3, 5, and 10 years were 16%, 3%, 2%, and none for the first sub-group; 46%, 20%, 17%, and 14% for the second; 65%, 53%, 29%, and 15% for the third; and 86%, 56%, 48%, and 41% for the fourth sub-group. The median survival in years was 0.30, 0.80, 3.10, and 4.40 for each sub-cohort, respectively. Conclusions The decrease and maintenance of VA depends on the initial VA of patients. Most patients experience a marked worsening of their VA, regardless of their VA status before treatment with episcleral brachytherapy. Patients with a higher baseline VA retain VA best over time.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135706348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose Several cases of inaccurate irradiation in brachytherapy have been reported, occurring similarly to external radiation. Due to a large dose per fraction in brachytherapy, inaccurate irradiation can seriously harm a patient. Although various studies have been conducted, systems that detect inaccurate irradiation in brachytherapy are not as developed as those for external irradiation. This study aimed to construct a system that analyzes the source dwell position during irradiation using computed tomography (CT) scout images. The novelty of the study was that by using CT scout images, high versatility and analysis of absolute coordinates can be achieved. Material and methods A treatment plan was designed with an iridium-192 (192Ir) source delivering radiation at two dwell positions in a tandem applicator. CT scout images were taken during irradiation, and acquired under different imaging conditions and applicator geometries. First, we confirmed whether a source was visible in CT scout images. Then, employing in-house MATLAB program, source dwell coordinates were analyzed using the images. An analysis was considered adequate when the resulting source dwell coordinates agreed with the treatment plan within ±1 mm, in accordance with AAPM TG56 guidelines for source dwell position accuracy. Results The source dwelling was visible in CT scout image, which was enlarged or reduced depending on applicator geometries. The applicator was enlarged by 127% when 130 mm away from the center of CT gantry. The analysis results using our in-house program were considered adequate; although, analysis parameters required adjustments depending on imaging conditions. Conclusions The proposed system can be easily implemented for image-guided brachytherapy and can analyze the absolute coordinates of source dwell position. Therefore, the system could be used for preventing inaccurate irradiation by verifying whether brachytherapy was performed properly.
{"title":"Analysis of source dwell position during treatment in brachytherapy using CT scout images","authors":"Nozomi Nakajima, Tomonori Isobe, Yoshinobu Furuyama, Tetsuya Tomita, Daisuke Kobayashi, Yutaro Mori, Hideyuki Takei, Yoshiaki Nagai, Yasuwo Ide, Keiko Nemoto Murofushi, Masaru Nakajima, Yasuo Yoshioka","doi":"10.5114/jcb.2023.132700","DOIUrl":"https://doi.org/10.5114/jcb.2023.132700","url":null,"abstract":"Purpose Several cases of inaccurate irradiation in brachytherapy have been reported, occurring similarly to external radiation. Due to a large dose per fraction in brachytherapy, inaccurate irradiation can seriously harm a patient. Although various studies have been conducted, systems that detect inaccurate irradiation in brachytherapy are not as developed as those for external irradiation. This study aimed to construct a system that analyzes the source dwell position during irradiation using computed tomography (CT) scout images. The novelty of the study was that by using CT scout images, high versatility and analysis of absolute coordinates can be achieved. Material and methods A treatment plan was designed with an iridium-192 (192Ir) source delivering radiation at two dwell positions in a tandem applicator. CT scout images were taken during irradiation, and acquired under different imaging conditions and applicator geometries. First, we confirmed whether a source was visible in CT scout images. Then, employing in-house MATLAB program, source dwell coordinates were analyzed using the images. An analysis was considered adequate when the resulting source dwell coordinates agreed with the treatment plan within ±1 mm, in accordance with AAPM TG56 guidelines for source dwell position accuracy. Results The source dwelling was visible in CT scout image, which was enlarged or reduced depending on applicator geometries. The applicator was enlarged by 127% when 130 mm away from the center of CT gantry. The analysis results using our in-house program were considered adequate; although, analysis parameters required adjustments depending on imaging conditions. Conclusions The proposed system can be easily implemented for image-guided brachytherapy and can analyze the absolute coordinates of source dwell position. Therefore, the system could be used for preventing inaccurate irradiation by verifying whether brachytherapy was performed properly.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135710673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emilia Zwolińska, Lidia Główka, Adam Chicheł, Iwona Rospond-Kubiak
AMA Zwolińska E, Główka L, Chicheł A, Rospond-Kubiak I. Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132401. APA Zwolińska, E., Główka, L., Chicheł, A., & Rospond-Kubiak, I. (2023). Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132401 Chicago Zwolińska, Emilia, Lidia Główka, Adam Chicheł, and Iwona Rospond-Kubiak. 2023. "Ruthenium brachytherapy for iris melanoma". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.132401. Harvard Zwolińska, E., Główka, L., Chicheł, A., and Rospond-Kubiak, I. (2023). Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132401 MLA Zwolińska, Emilia et al. "Ruthenium brachytherapy for iris melanoma." Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.132401. Vancouver Zwolińska E, Główka L, Chicheł A, Rospond-Kubiak I. Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132401.
AMA Zwolińska E, Główka L, Chicheł A, Rospond-Kubiak I. Ruthenium brachytherapy for iris melanoma.当代近距离治疗杂志》。2023. doi:10.5114/jcb.2023.132401.APA Zwolińska, E., Główka, L., Chicheł, A., & Rospond-Kubiak, I. (2023)。用于虹膜黑色素瘤的钌近距离放射治疗。https://doi.org/10.5114/jcb.2023.132401 Chicago Zwolińska, Emilia, Lidia Główka, Adam Chicheł, and Iwona Rospond-Kubiak.2023."治疗虹膜黑色素瘤的钌近距离放射疗法》。doi:10.5114/jcb.2023.132401。Harvard Zwolińska, E., Główka, L., Chicheł, A., and Rospond-Kubiak, I. (2023).治疗虹膜黑色素瘤的钌近距离放射疗法。https://doi.org/10.5114/jcb.2023.132401 MLA Zwolińska, Emilia et al. "虹膜黑色素瘤的钌近距离治疗"。Doi:10.5114/jcb.2023.132401.Vancouver Zwolińska E, Główka L, Chicheł A, Rospond-Kubiak I. Ruthenium brachytherapy for iris melanoma.当代近距离治疗杂志》。2023. doi:10.5114/jcb.2023.132401.
{"title":"Ruthenium brachytherapy for iris melanoma","authors":"Emilia Zwolińska, Lidia Główka, Adam Chicheł, Iwona Rospond-Kubiak","doi":"10.5114/jcb.2023.132401","DOIUrl":"https://doi.org/10.5114/jcb.2023.132401","url":null,"abstract":"AMA Zwolińska E, Główka L, Chicheł A, Rospond-Kubiak I. Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132401. APA Zwolińska, E., Główka, L., Chicheł, A., & Rospond-Kubiak, I. (2023). Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132401 Chicago Zwolińska, Emilia, Lidia Główka, Adam Chicheł, and Iwona Rospond-Kubiak. 2023. \"Ruthenium brachytherapy for iris melanoma\". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.132401. Harvard Zwolińska, E., Główka, L., Chicheł, A., and Rospond-Kubiak, I. (2023). Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132401 MLA Zwolińska, Emilia et al. \"Ruthenium brachytherapy for iris melanoma.\" Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.132401. Vancouver Zwolińska E, Główka L, Chicheł A, Rospond-Kubiak I. Ruthenium brachytherapy for iris melanoma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132401.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135211032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Melisa Pasli, Sara Cowles, Jasmin Jo, Mahmoud Yaqoub, Hilal A. Kanaan, Andrew W. Ju, Sean Peach
AMA Pasli M, Cowles S, Jo J, et al. First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132083. APA Pasli, M., Cowles, S., Jo, J., Yaqoub, M., Kanaan, H., & Ju, A. et al. (2023). First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132083 Chicago Pasli, Melisa, Sara Cowles, Jasmin Jo, Mahmoud Yaqoub, Hilal A. Kanaan, Andrew W. Ju, and Sean Peach. 2023. "First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.132083. Harvard Pasli, M., Cowles, S., Jo, J., Yaqoub, M., Kanaan, H., Ju, A., and Peach, S. (2023). First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132083 MLA Pasli, Melisa et al. "First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma." Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.132083. Vancouver Pasli M, Cowles S, Jo J, Yaqoub M, Kanaan H, Ju A et al. First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132083.
张建军,张建军,张建军,等。首次应用GammaTile铯-131近距离放射治疗最大限度安全切除胶质瘤在局限性硬皮病患者中的应用。当代近距离放射治疗杂志。2023。doi: 10.5114 / jcb.2023.132083。APA Pasli, M, Cowles, S., Jo, J., Yaqoub, M, Kanaan, H., & Ju, A.等(2023)。首次应用GammaTile铯-131近距离放射治疗最大限度安全切除胶质瘤在局限性硬皮病患者中的应用。当代近距离放射治疗杂志。https://doi.org/10.5114/jcb.2023.132083 Chicago Pasli, melissa, Sara Cowles, Jasmin Jo, Mahmoud Yaqoub, Hilal A. Kanaan, Andrew W. Ju, and Sean Peach. 2023。“GammaTile铯-131近距离放射治疗在局限性硬皮病患者中最大限度安全切除胶质瘤的首次应用”。当代近距离放射治疗杂志。doi: 10.5114 / jcb.2023.132083。Harvard Pasli, M, Cowles, S., Jo, J., Yaqoub, M., Kanaan, H., Ju, A.和Peach, S.(2023)。首次应用GammaTile铯-131近距离放射治疗最大限度安全切除胶质瘤在局限性硬皮病患者中的应用。当代近距离放射治疗杂志。https://doi.org/10.5114/jcb.2023.132083 MLA Pasli, Melisa等。“首次应用GammaTile铯-131近距离放射治疗,最大限度安全切除胶质瘤,治疗局限性硬皮病患者。”当代近距离放射治疗杂志,2023。doi: 10.5114 / jcb.2023.132083。王晓明,王晓明,王晓明,等。首次应用GammaTile铯-131近距离放射治疗最大限度安全切除胶质瘤在局限性硬皮病患者中的应用。当代近距离放射治疗杂志。2023。doi: 10.5114 / jcb.2023.132083。
{"title":"First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma","authors":"Melisa Pasli, Sara Cowles, Jasmin Jo, Mahmoud Yaqoub, Hilal A. Kanaan, Andrew W. Ju, Sean Peach","doi":"10.5114/jcb.2023.132083","DOIUrl":"https://doi.org/10.5114/jcb.2023.132083","url":null,"abstract":"AMA Pasli M, Cowles S, Jo J, et al. First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132083. APA Pasli, M., Cowles, S., Jo, J., Yaqoub, M., Kanaan, H., & Ju, A. et al. (2023). First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132083 Chicago Pasli, Melisa, Sara Cowles, Jasmin Jo, Mahmoud Yaqoub, Hilal A. Kanaan, Andrew W. Ju, and Sean Peach. 2023. \"First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma\". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.132083. Harvard Pasli, M., Cowles, S., Jo, J., Yaqoub, M., Kanaan, H., Ju, A., and Peach, S. (2023). First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132083 MLA Pasli, Melisa et al. \"First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma.\" Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.132083. Vancouver Pasli M, Cowles S, Jo J, Yaqoub M, Kanaan H, Ju A et al. First application of GammaTile cesium-131 brachytherapy with maximal safe resection of a glioma in a patient with limited scleroderma. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132083.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135059220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Baoxi Liu, Yaqin Wu, Li Sun, Chang Guo, Qi Wang, Zhongde Mu
AMA Liu B, Wu Y, Sun L, Guo C, Wang Q, Mu Z. Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy. 2023;15(5):325-333. doi:10.5114/jcb.2023.132695. APA Liu, B., Wu, Y., Sun, L., Guo, C., Wang, Q., & Mu, Z. (2023). Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy, 15(5), 325-333. https://doi.org/10.5114/jcb.2023.132695 Chicago Liu, Baoxi, Yaqin Wu, Li Sun, Chang Guo, Qi Wang, and Zhongde Mu. 2023. "Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer". Journal of Contemporary Brachytherapy 15 (5): 325-333. doi:10.5114/jcb.2023.132695. Harvard Liu, B., Wu, Y., Sun, L., Guo, C., Wang, Q., and Mu, Z. (2023). Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy, 15(5), pp.325-333. https://doi.org/10.5114/jcb.2023.132695 MLA Liu, Baoxi et al. "Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer." Journal of Contemporary Brachytherapy, vol. 15, no. 5, 2023, pp. 325-333. doi:10.5114/jcb.2023.132695. Vancouver Liu B, Wu Y, Sun L, Guo C, Wang Q, Mu Z. Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy. 2023;15(5):325-333. doi:10.5114/jcb.2023.132695.
{"title":"Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer","authors":"Baoxi Liu, Yaqin Wu, Li Sun, Chang Guo, Qi Wang, Zhongde Mu","doi":"10.5114/jcb.2023.132695","DOIUrl":"https://doi.org/10.5114/jcb.2023.132695","url":null,"abstract":"AMA Liu B, Wu Y, Sun L, Guo C, Wang Q, Mu Z. Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy. 2023;15(5):325-333. doi:10.5114/jcb.2023.132695. APA Liu, B., Wu, Y., Sun, L., Guo, C., Wang, Q., & Mu, Z. (2023). Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy, 15(5), 325-333. https://doi.org/10.5114/jcb.2023.132695 Chicago Liu, Baoxi, Yaqin Wu, Li Sun, Chang Guo, Qi Wang, and Zhongde Mu. 2023. \"Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer\". Journal of Contemporary Brachytherapy 15 (5): 325-333. doi:10.5114/jcb.2023.132695. Harvard Liu, B., Wu, Y., Sun, L., Guo, C., Wang, Q., and Mu, Z. (2023). Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy, 15(5), pp.325-333. https://doi.org/10.5114/jcb.2023.132695 MLA Liu, Baoxi et al. \"Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer.\" Journal of Contemporary Brachytherapy, vol. 15, no. 5, 2023, pp. 325-333. doi:10.5114/jcb.2023.132695. Vancouver Liu B, Wu Y, Sun L, Guo C, Wang Q, Mu Z. Dosimetry and plan parameters study of three-dimensional-printed template-based intra-cavitary/interstitial interpolation technology using computed tomography-guided high-dose-rate brachytherapy in locally advanced cervical cancer. Journal of Contemporary Brachytherapy. 2023;15(5):325-333. doi:10.5114/jcb.2023.132695.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135710046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marija Živković Radojević, Srđan Mujković, Protrka Zoran, Dragan Lončar, Nikola Nedović, Jasmina Nedović, Radiša Vojinović, Aleksandra Dimitrijević, Tatjana Vulović, Neda Milosavljević
AMA Radojević M, Mujković S, Zoran P, et al. Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132191. APA Radojević, M., Mujković, S., Zoran, P., Lončar, D., Nedović, N., & Nedović, J. et al. (2023). Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132191 Chicago Radojević, Marija Živković, Srđan Mujković, Protrka Zoran, Dragan Lončar, Nikola Nedović, Jasmina Nedović, and Radiša Vojinović et al. 2023. "Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.132191. Harvard Radojević, M., Mujković, S., Zoran, P., Lončar, D., Nedović, N., Nedović, J., Vojinović, R., Dimitrijević, A., Vulović, T., and Milosavljević, N. (2023). Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132191 MLA Radojević, Marija Živković et al. "Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country." Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.132191. Vancouver Radojević M, Mujković S, Zoran P, Lončar D, Nedović N, Nedović J et al. Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132191.
张建军,张建军,张建军,等。FIGO IA期子宫内膜癌患者的5年无病生存率:发展中国家高等教育机构的经验当代近距离放射治疗杂志。2023。doi: 10.5114 / jcb.2023.132191。APA radojeviki, M., mujkoviki, S., Zoran, P., lon, D., nedoviki, N., & nedoviki, J.等人(2023)。FIGO IA期子宫内膜癌患者的5年无病生存率:发展中国家高等教育机构的经验当代近距离放射治疗杂志。https://doi.org/10.5114/jcb.2023.132191 Chicago radojeviki, Marija Živković, Srđan mujkoviki, Protrka Zoran, Dragan lon, Nikola nedoviki, Jasmina nedoviki, and Radiša vojinoviki et al. 2023。FIGO IA期子宫内膜癌患者的5年无病生存率:发展中国家高等教育机构的经验。当代近距离放射治疗杂志。doi: 10.5114 / jcb.2023.132191。哈佛拉多耶维奇,M.,穆伊科维奇,S., Zoran, P., lon, D.,涅多维奇,N.,涅多维奇,J.,沃吉诺维奇,R.,迪米特里耶维奇,A.,武洛维奇,T.,和米洛萨夫耶维奇,N.(2023)。FIGO IA期子宫内膜癌患者的5年无病生存率:发展中国家高等教育机构的经验当代近距离放射治疗杂志。https://doi.org/10.5114/jcb.2023.132191 MLA radojeviki, Marija Živković等。FIGO IA期子宫内膜癌患者的5年无病生存率:发展中国家高等教育机构的经验。当代近距离放射治疗杂志,2023。doi: 10.5114 / jcb.2023.132191。刘建军,刘建军,刘建军,等。FIGO IA期子宫内膜癌患者的5年无病生存率:发展中国家高等教育机构的经验当代近距离放射治疗杂志。2023。doi: 10.5114 / jcb.2023.132191。
{"title":"Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country","authors":"Marija Živković Radojević, Srđan Mujković, Protrka Zoran, Dragan Lončar, Nikola Nedović, Jasmina Nedović, Radiša Vojinović, Aleksandra Dimitrijević, Tatjana Vulović, Neda Milosavljević","doi":"10.5114/jcb.2023.132191","DOIUrl":"https://doi.org/10.5114/jcb.2023.132191","url":null,"abstract":"AMA Radojević M, Mujković S, Zoran P, et al. Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132191. APA Radojević, M., Mujković, S., Zoran, P., Lončar, D., Nedović, N., & Nedović, J. et al. (2023). Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132191 Chicago Radojević, Marija Živković, Srđan Mujković, Protrka Zoran, Dragan Lončar, Nikola Nedović, Jasmina Nedović, and Radiša Vojinović et al. 2023. \"Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country\". Journal of Contemporary Brachytherapy. doi:10.5114/jcb.2023.132191. Harvard Radojević, M., Mujković, S., Zoran, P., Lončar, D., Nedović, N., Nedović, J., Vojinović, R., Dimitrijević, A., Vulović, T., and Milosavljević, N. (2023). Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. https://doi.org/10.5114/jcb.2023.132191 MLA Radojević, Marija Živković et al. \"Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country.\" Journal of Contemporary Brachytherapy, 2023. doi:10.5114/jcb.2023.132191. Vancouver Radojević M, Mujković S, Zoran P, Lončar D, Nedović N, Nedović J et al. Five-year disease-free survival in FIGO IA stage endometrial cancer patients: Tertiary institution experience in a developing country. Journal of Contemporary Brachytherapy. 2023. doi:10.5114/jcb.2023.132191.","PeriodicalId":51305,"journal":{"name":"Journal of Contemporary Brachytherapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135059225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}